Weight Loss Results from Zepbound 15 mg in Clinical Trials
In the SURMOUNT-1 trial, adults with obesity or overweight (plus comorbidities) on the highest dose of tirzepatide—15 mg weekly, equivalent to Zepbound—lost an average of 20.9% of body weight after 72 weeks, or about 52 pounds for a 250-pound person.[1] This outperformed placebo (3% loss) and lower doses (15 mg beat 10 mg's 19.5% and 5 mg's 15%). Over 80% of participants hit at least 5% loss, with many reaching 20-25%.[1][2]
How Weight Loss Builds Over Time on 15 mg
Loss accelerates after dose escalation (starting at 2.5 mg, ramping to 15 mg by week 20). By week 20: ~12% loss. By week 52: ~18%. Peak at week 72: 20.9%, with minimal regain during maintenance.[1] SURMOUNT-2 (with type 2 diabetes) showed slightly less: 15.7% average loss on 15 mg.[3]
Factors Affecting Individual Results
Real-world loss varies by starting weight, diet, exercise, and adherence. Women often lose more percentage-wise; men more absolute pounds. About 10-15% see under 10% loss due to genetics or side effects like nausea limiting tolerance.[2][4] Combining with lifestyle changes boosts outcomes—trials mandated 500-calorie deficits and 150 minutes weekly exercise.
Comparison to Lower Doses and Competitors
| Dose | Avg. % Weight Loss (72 Weeks, SURMOUNT-1) |
|------|-------------------------------------------|
| 5 mg | 15% |
| 10 mg | 19.5% |
| 15 mg | 20.9% |
| Placebo | 3% |
Zepbound 15 mg edges semaglutide (Wegovy 2.4 mg): 15% loss in head-to-head data.[5] Mounjaro (same drug) matches these numbers off-label.
Side Effects and Why Some Lose Less
Common issues—nausea (30%), diarrhea (20%)—peak early but drop; severe GI problems cause 5-7% dropout.[1] Muscle loss (25-40% of total) occurs without resistance training; monitor with DEXA scans.[4] Not for under 30 BMI without issues; heart risks in trials were low.
Cost and Access for 15 mg
~$1,000/month without insurance; coupons cut to $550 for cash-pay. Compounded versions cheaper but riskier (FDA warnings).[6] Patents last to 2036; generics unlikely soon.[7]
[1] NEJM: Tirzepatide Once Weekly for Obesity (SURMOUNT-1), 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[2] Lilly SURMOUNT-1 Data. https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-achieved-209-average-weight-loss-adults-obesity
[3] Lilly SURMOUNT-2 Data. https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-significantly-reduced-157-average-weight-adults
[4] JAMA: GLP-1 Muscle Loss Review, 2023. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2812752
[5] Lilly SURMOUNT-5 Head-to-Head. https://investor.lilly.com/news-releases/news-release-details/lillys-zepboundr-tirzepatide-superior-wegovyr-semaglutide-head
[6] FDA Compounding Alert. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-not-to-use-certain
[7] DrugPatentWatch: Zepbound Patents. https://www.drugpatentwatch.com/p/tradename/ZEPBOUND